SCOR-LUNG BIOLOGY AND DISEASES IN INFANTS AND CHILDREN

婴儿和儿童的 SCOR-肺生物学与疾病

• 批准号: 3106905
• 负责人: JOHN P. REEVES
• 金额: $ 94.57万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 1991
• 资助国家: 美国
• 起止时间: 1991-12-30 至 1996-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3106905
• 关键词: human subject; newborn human (0-6 weeks); pulmonary hypertension

This proposal from the Department of Pediatrics, University of Colorado, seeks 5 year funding to establish a new program which investigates persistent pulmonary hypertension of the newborn (PPHN). PPHN is a relatively frequent (1:500 live births) disease of unknown origin associated with a high morbidity and mortality (25-50%) unless treated for days with invasive, expensive, and somewhat risky extracorporeal membrane oxygenation (ECMO). We propose to investigate initial insults (such as oxidant and hemodynamic stress) and mechanisms through which these insults lead to altered vasoreactivity and vascular remodeling (increased matrix, and vascular cell proliferation), clinical hallmarks of PPHN. Available for study are approximately 80-100 patients per year with established PPHN referred to The Children's Hospital, Denver, and 20 born to a high risk population at the University Hospital, where early detection procedures have been developed. Basic insights into mechanisms operating in PPHN will be from the patients, several animal models of neonatal pulmonary hypertension, and cellular and molecular studies. The data will allow early detection and interventions and better therapies aimed at effective vasodilation and restoration of depleted antioxidant defenses. The program will provide early detection, better treatment, and ultimately, prevention, of PPHN.

这项提案来自科罗拉多大学儿科系 寻求5年的资金来建立一个新计划，以调查 新生儿（PPHN）的持续性肺动脉高压。 pphn是一个 相对频繁的（1：500活出生）的起源疾病 与高发病率和死亡率相关（25-50％），除非治疗 在侵入性，昂贵且有些风险的体外数天 膜氧合（ECMO）。 我们建议研究最初的损伤（例如氧化剂和 血液动力学压力）和这些侮辱导致的机制 血管反应性和血管重塑的改变（基质增加，并且 血管细胞增殖），PPHN的临床标志。 可用于研究的每年约80-100名患者 已建立的PPHN转交给儿童医院，丹佛和20 出生于大学医院的高风险人口，早期 已经开发了检测程序。对机制的基本见解 在PPHN中运作的将来自患者，几种动物模型 新生儿肺动脉高压以及细胞和分子研究。这 数据将允许早期检测和干预措施以及更好的疗法 旨在有效的血管舒张和恢复耗尽的抗氧化剂 防御。该计划将提供早期检测，更好的治疗， 最终，PPHN的预防。